Cenedella.de

Patient Advocate since 1977.


Leave a comment

Germany’s largest legal cannabis plantation – by VICE Magazine

https://www.vice.com/de/article/qvjge5/weed-aus-dem-atombunker-dieser-typ-baut-deutschlands-grosste-legale-cannabis-plantage

http://www.bunker-ppd.de/

Germany’s largest legal cannabis plantation
Tim Geyer
Oct. 17 2017, 3:20 pm
Because of grass dealings, Christoph Roßner had already been in prison for five months. Today he works with Bavarian politicians.

This is not really a loose work place, even if grass is to be cultivated, says Christoph Roßner. The Atombunker, before which he stands, is squeezed between car parks and fields in the Allgäu countryside like a stranded oil tank. Here, from the former Fliegerhorst Memmingerberg NATO would have led the nuclear counterattack, had the Cold War escalated. Today the entrepreneur wants to breed cannabis in the bunker. Green haze instead of black rain – within sight of a federal police station and with the blessing of the Bavarian government. Since the beginning of the year, cannabis is legal on prescription in Germany and Rossner’s sentiment is that of a brewer’s owner after the end of the prohibition: “We have the chance to become one of the biggest players in the international cannabis market.”

Alone for 2015, the German Monitoring Center for Drugs and Drug Abuse (DBDD) counts almost five million Germans who have consumed cannabis at least once during the last twelve months. The dark figure should be even higher. Activists and businessmen have taken this first step towards legalization. Christoph Roßner is both. And also looks like this: black jacket over black sweater, the gray hair tamed to the horse tail. Business in the front, party in the back.

One of the many lock gates between the individual bunkers
From the war machine to the grass factory

The bunker, a 50-meter-long, 15-meter high colossus, with its aerial storms acts like a medieval fortress. From 1985, the Luftwaffe soldiers of the Jagdbombersgeschwader 34 were sitting here, servicing the control systems for the nearby rocket silos. “This bunker is safer than a nuclear waste disposal site, but we want to grow plants here,” says the 47-year-old. He has previously registered with the neighboring Federal Police Station on the visit of the journalists.

The Panzertor groans aside. 175 tons of hardened steel, eight meters wide, nearly one meter thick. A siren howls like a submarine on a dive. Through the opening one reaches the actual bunker, which surrounds the outer wall as the reactor coherent of Chernobyl. Then another lock door, another 30 centimeters of steel. Later, 15 employees of Roßner’s company Bunker PPD, which he wants to adjust, will change the street clothes against overalls without bags and scan their fingerprints. The few, the income, will be nothing to take with. Roßner leads past former team rooms and the radio center, a five-meter-thick steel-concrete ceiling above us. You go ducked, even though you do not have to.

But no matter how many nights Roßner is working on his business plans, in the end others decide: the Federal Institute for Drugs and Medical Devices and the Bundespiumstelle, which is subordinate to him. Anyone who wants to produce or use drugs in Germany must either talk to them or seek a good lawyer. But once the TÜV seal of the Panzertür has expired, once the officials discover a tiny mistake in a request: the bureaucrats are editing Roßner, the changing Würgreiz for CSU politicians, so meticulously as if they Franz Josef Strauss’ last will.

Where the radio had previously been monitored, a cannabis laboratory could soon be available
From activist to cannabis entrepreneur

Roßner knows this. For the last three decades he has been working on the legalization of cannabis. Two key experiences are the reason: at 17 he smokes his first joint. He notes: Kiffen helps him to curb his hyperactivity. A year later a steel carrier crushed his left shoulder during his training as an industrial mechanic. Against the chronic pain smokes Roßner cannabis. To this day, now on recipe. “If you like, I’m just tight,” he says. In 1994, a friend of Roßner, who suffers from epilepsy, finds out that marijuana dampens his attacks. Roessner’s sister also suffered from epilepsy. For them, this knowledge comes too late. Two years before, she committed suicide. “I could have helped her,” says Rossner.

From this moment on, he is on a mission: He is worried about marijuana to help others, he says. “Illegal research” he calls this. At that time, as today, cannabis is prohibited by law in Germany. It is only since 1 March 2017 that doctors can prescribe – even without the hard-to-obtain exemption. Although in 1994, the Federal Constitutional Court ruled that a small quantity of cannabis can be carried with no prescription – depending on the federal state, between five and ten grams – this verdict does not, however, protect against criminal prosecution. This is what the courts alone decide. Roessner also knew about the risk, especially in Bavaria, When it is rumored that he is running a kind of private hemp pharmacy, more and more people are coming. Rheumatics, neurodermatitis, chemotherapy patients. And some policemen.

If at any time the electricity should fail, Roßner can take advantage of four diesel generators to supply his cannabis lantern with light
Roßner is sentenced: two years and one month. He spends five months in prison and four in therapy. It’s been 17 years now. When he rages, he knocks again at his doorstep. Still, people who have pain are coming. Roßner does not do any illegal business, he continues to believe in the medical benefits of cannabis. Together with the Chair of Chemistry at the Technical University of Munich and the University of British Columbia, he is currently preparing a study to investigate the effects of the most important medicinal hemp varieties and to develop quality standards for them. 150 patients he wants to provide cannabis from his bunker. Will the study and the necessary hemp cultivation be approved, this would be his first decisive step to enter the medical cannabis market. The study is intended to prove that he, the ex-prisoner, is serious.

Politicians, investors and business bosses listen to him

By working with the universities, Roßner hopes that the newly established state-owned cannabis agency will choose him to produce state-certified grass. The agency is to provide patients with marijuana from Germany and is looking for producers all over Europe. In addition to Rossner, other German entrepreneurs are also applying, for example SensHemp from Berlin and Hanf AG from Hamburg. 2,000 kilograms per year, the agency estimates, would have to grow on German plantings in 2021 and 2022 to supply all patients. Roßner believes that German patients need six times a year: over 12 tonnes of grass. If no one has to apply for an exemption, but only needs a prescription, more patients will take this step, he is sure. In addition, it would not be worth it to build a plant worth several million euros. But without permission for the study, he could set up his bunker to a very unpleasant country house.

Plantation air could soon flow through the ventilation towers
Just a strong CSU conservative helps him with his plan. Franz Josef Pschierer, State Secretary in the Bavarian Ministry of Economic Affairs, will bring him together with entrepreneurs and politicians from Bavaria in 2016. Roßner tells them about the unused economic potential, possible tax revenues and savings in the police and courts. “Without the help of the Bavarian government, no one would listen to me,” he says. He is now planning his cannabis breeding plant with ThyssenKrupp – and is holding talks with internationally active hedge funds. If they invest in it, the Free State of Bavaria could subsidize its business with about a quarter of a million euros. From tax money. Marijuana sponsored by Horst Seehofer.

In many places in the bunker the soldiers have left something behind
While Roßner sketched his battle plan for the next months, we descend deeper into the airtight crypt. There is neither mobile phone reception nor spiderwebs. Comic paintings on the walls testify to what the soldiers were busy with when they were bored to wait for the Third World War. In one room there are vault chambers, large as overseas containers. Here the mother plants could grow. “Lamps clean, connect ventilation, let’s go,” says Roßner, “more perfect conditions than here you will find nowhere.” A high-security laboratory is to move into the former squadron headquarters. Here, chemists could clone potent cannabis varieties. Next to it stands an industrial furnace, in which former toxins were destroyed at 900 degrees. In the future, the most serious of these will be burned. A few security doors: the space for the cuttings. “We start with 80 different varieties,” Roßner says self-confidently, as if he had the approval already.

In these cabinets Roßner wants to breed young plants
Race with the Dutch

Sometimes Christoph Rossner would ask the same as the early fans of Cherry Coke or anal whitening: When will the backward-looking Germans finally understand what the Americans have long been celebrating? In 29 out of 50 US states , medical cannabis has been allowed or grass has been fully legalized. In 2016, the industry generated sales of 6.7 billion US dollars . Until it is so far in Germany, Rossner will still have to smoke a few blunts on the recipe.

At the beginning of the year, he was sitting with his lawyers to prepare a lawsuit against the Federal Institute for Drugs, he tells us as we step out of the darkness of the bunker. The agency has asked potential medical producers that they have already grown, processed and delivered at least 50 kilograms over the last three years. How is he to apply, if exactly that in Germany so far was illegal, Roßner curses. It is not easy to get a mission in Germany for something that does not really exist at all.

Meanwhile, the authorities want to improve – a small victory, but Rossner is running out of time. The Dutch company Sensi Seeds systematically purchases small cannabis producers in the USA and is now pushing into the German market. Roßner does not want to be bought up. His research project will start in March, followed by commercial operations. He wants to make money himself and make the world a bit better with nothing but a few plants from a Bavarian atomic bomb.

Follow VICE on Facebook , Instagram and Snapchat .

Advertisements


Leave a comment

“10 diseases where medical marijuana could have impact”

Medical reporter Jen Christensen of CNN authored an article “10 diseases where medical marijuana could have impact” detailing the 10 ailments most commonly treated with medicinal marijuana. I have listed them here, exactly as she had written to maintain the accuracy and links she provided.

AIDS/HIV

In a human study of 10 HIV-positive marijuana smokers, scientists found people who smoked marijuana ate better, slept better and experienced a better mood. Another small study of 50 people found patients that smoked cannabis saw less neuropathic pain.

Alzheimer’s

Medical marijuana and some of the plant’s chemicals have been used to help Alzheimer’s patients gain weight, and research found that it lessens some of the agitated behavior that patients can exhibit. In one cell study, researchers found it slowed the progress of protein deposits in the brain. Scientists think these proteins may be part of what causes Alzheimer’s, although no one knows what causes the disease.

Arthritis

A study of 58 patients using the derivatives of marijuana found they had less arthritis pain and slept better. Another review of studies concluded marijuana may help fight pain-causing inflammation.

Asthma

Studies are contradictory, but some early work suggests it reduced exercise-induced asthma. Other cell studies showed smoking marijuana could dilate human airways, but some patients experienced a tight feeling in their chests and throats. A study in mice found similar results.

Cancer

Animal studies have shown some marijuana extracts may kill certain cancer cells. Other cell studies show it may stop cancer growth, and with mice, THC, the psychoactive ingredient in marijuana, improved the impact of radiation on cancer cells. Marijuana can also prevent the nausea that often accompanies chemotherapy treatment used to treat cancer.

Chronic pain

Some animal and small human studies show that cannabinoids can have a “substantial analgesic effect.” People widely used them for pain relief in the 1800s. Some medicines based on cannabis such as Sativex are being tested on multiple sclerosis patients and used to treat cancer pain. The drug has been approved in Canada and in some European countries. In another trial involving 56 human patients, scientists saw a 30% reduction in pain in those who smoked marijuana.

Crohn’s disease

In a small pilot study of 13 patients watched over three months, researchers found inhaled cannabis did improve life for people suffering from ulcerative colitis and Crohn’s disease. It helped ease people’s pain, limited the frequency of diarrhea and helped with weight gain.

Epilepsy

Medical marijuana extract in early trials at the NYU Langone Medical Center showed a 50% reduction in the frequency of certain seizures in children and adults in a study of 213 patients recently.

Glaucoma

Glaucoma is one of the leading causes of blindness. Scientists have looked at THC’s impact on this disease on the optic nerve and found it can lower eye pressure, but it may also lower blood pressure, which could harm the optic nerve due to a reduced blood supply. THC can also help preserve the nerves, a small study found.

Multiple sclerosis

Using marijuana or some of the chemicals in the plant may help prevent muscle spasms, pain, tremors and stiffness, according to early-stage, mostly observational studies involving animals, lab tests and a small number of human patients. The downside — it may impair memory, according to a small study involving 20 patients.

On November 1 at the Hilton Naples MyFloridaGreen.com is hosting an unprecedented Educational Symposium: CANNABIS SPEAKS. Featuring the most sought-after industry experts to discuss the profound benefits cannabis offers for conditions like Cancer, Epilepsy, Glaucoma, HIV/AIDS, Post-traumatic stress disorder, ALS, Crohn’s disease, Parkinson’s disease, or Multiple sclerosis.


Leave a comment

“The unjust prohibition of marijuana has done more damage to public health than has marijuana itself.” – former U.S. Surgeon General Joycelyn Elders

In a new article appearing in next month’s American Journal of Public Health, a number of leading doctors and health experts, including former U.S. Surgeon General Joycelyn Elders, are calling for the total legalization of cannabis.

“The war on marijuana exacerbates poverty, which is strongly correlated with— among other problems—reduced access to health care,” Elders writes. “The unjust prohibition of marijuana has done more damage to public health than has marijuana itself.”

According to Marijuana Moment, Elders has advocated for drug reform since serving as Surgeon General under the Clinton administration. In 1993, she said that she believed that the country would “markedly reduce our crime rate if drugs were legalized.” Twenty-four years later, Elders notes that “times are changing. In 2017, even physicians who oppose legalization generally believe that marijuana should be decriminalized, reducing penalties for users while keeping the drug illegal.”

Elders, along with co-authors Dr. David L. Nathan and former director of the Center for Substance Abuse Treatment at the Substance Abuse and Mental Health Services Administration H. Westley Clark, used their space in the Journal of Public Health to make clear their belief that decriminalization alone is not an effective solution to the problems caused by cannabis prohibition. “Although decriminalization is certainly a step in the right direction, [it is] an inadequate substitute for legalization and regulation for a number of reasons,” they wrote.

“Decriminalization does not empower the government to regulate product labeling and purity, which leaves marijuana vulnerable to contamination and adulteration,” the doctors explain. “This also renders consumers unable to judge the potency of marijuana, which is like drinking alcohol without knowing its strength. Moreover, where marijuana is merely decriminalized, the point of sale remains in the hands of drug dealers, who will sell marijuana— as well as more dangerous drugs—to children.”

“Contrary to popular belief, decriminalization does not actually end the arrests of marijuana users,” the article continues. “Despite New York State decriminalizing marijuana in the 1970s, New York City makes tens of thousands of marijuana possession arrests every year, with continuing racial disparities in enforcement.”

The doctors also describe how the prosecution of illegal cannabis growers and sellers constricts the supply chain, increasing the price of illegal cannabis as well as “making the untaxed illegal product more lucrative, the market for it more competitive and violent, and purchasing it more dangerous.”

While legalization is spreading up and down the coasts, decriminalization is still the highest point of marijuana reform for municipalities in states with strong anti-cannabis leadership.

Elders was ousted from her position as Surgeon General in 1994 because of her progressive ideas about drugs and sex, and now, with cannabis closer to the mainstream than ever before and sex-positive attitudes prevalent across American culture, hopefully, 23 years later, the country’s decision makers will finally realize that she’s been right all along.

Published on October 14, 2017
Chris Moore is a New York-based writer who has written for Mass Appeal while also mixing records and producing electronic music.
https://merryjane.com/news/former-surgeon-general-joycelyn-elders-legalization-support


Leave a comment

Physician Guide to Cannabis-Assisted Opioid Reduction Prepared by Adrianne Wilson-Poe, Ph.D. Distributed by Congressman Earl Blumenauer

Physician Guide to Cannabis-Assisted Opioid Reduction
Prepared by Adrianne Wilson-Poe, Ph.D.
Distributed by Congressman Earl Blumenauer
Cannabis reduces opioid overdose mortality.
• In states with medicinal cannabis laws, opioid overdoses drop by an average of 25%. This effect gets
bigger the longer the law has been in place. For instance, there is a 33% drop in mortality in California,
where compassionate use has been in place since 1996 (1).
• This finding was replicated by Columbia’s school of public health, using a completely different analysis
strategy (2).
Cannabis reduces opioid consumption.
• Cannabis is opioid-sparing in chronic pain patients. When patients are given access to cannabis, they
drop their opioid use by roughly 50%. This finding has been replicated several times from Ann Arbor to
Jerusalem (3, 4).
• This opioid sparing effect is accompanied by an enhancement of cognitive function once patients begin
cannabis therapy: this effect is most likely due to the fact that patients reduce their opioid use (5).
• Cannabis use is associated with a reduction in not only opioid consumption, but also many other drugs
including benzodiazepines, which also have a high incidence of fatal overdose. In states with medicinal
cannabis laws, the number of prescriptions for analgesic and anxiolytic drugs (among others) are
substantially reduced (6). Medicare and Medicaid prescription costs are substantially lower in states
with cannabis laws (7).
Cannabis can prevent dose escalation and the development of opioid tolerance.
• Cannabinoids and opioids have acute analgesic synergy. When opioids and cannabinoids are
coadministered, they produce greater than additive analgesia (8). This suggests that analgesic dose of
opioids is substantially lower for patients using cannabis therapy.
• In chronic pain patients on opioid therapy, cannabis does not affect pharmacokinetics of opioids, yet it
still enhances analgesia. This finding further supports a synergistic mechanism of action (9).
• Pre-clinical models indicate that cannabinoids attenuate the development of opioid tolerance (10, 11).
Cannabis, alone or in combination with opioids, could be a viable first-line analgesic.
• The CDC has updated its recommendations in the spring of 2016, stating that most cases of chronicpain
should be treated with non-opioids (12).
• The National Academies of Science and Medicine recently conducted an exhaustive review of 10,000+
human studies published since 1999, definitively concluding that cannabis itself (not a specific
cannabinoid or cannabis-derived molecule) is safe and effective for the treatment of chronic pain (13).
• When 3,000 chronic pain patients were surveyed, they overwhelmingly preferred cannabis as an opioid
alternative (14).
o 97% “strongly agreed/agreed” that they could decrease their opioid use when using cannabis
o 92% “strongly agreed/agreed” that they prefer cannabis to treat their medical condition
o 81% “strongly agreed/ agreed that cannabis by itself was more effective than taking opioids
Cannabis may be a viable tool in medication-assisted relapse prevention
• CBD is non-intoxicating, and is the 2nd most abundant cannabinoid found in cannabis. CBD alleviates
the anxiety that leads to drug craving. In human pilot studies, CBD administration is sufficient to
prevent heroin craving for at least 7 days (15).
• Cannabis users are more likely to adhere to naltrexone maintenance for opioid dependence (16).
Bibliography and References Cited
1. Bachhuber MA, Saloner B, Cunningham CO, Barry CL. Medical cannabis laws and opioid analgesic overdose
mortality in the United States, 1999-2010. JAMA Intern Med. 2014;174(10):1668-73. doi:
10.1001/jamainternmed.2014.4005. PubMed PMID: 25154332; PMCID: 4392651.
2. Kim JH, Santaella-Tenorio J, Mauro C, Wrobel J, Cerda M, Keyes KM, Hasin D, Martins SS, Li G. State Medical
Marijuana Laws and the Prevalence of Opioids Detected Among Fatally Injured Drivers. Am J Public Health.
2016;106(11):2032-7. doi: 10.2105/AJPH.2016.303426. PubMed PMID: 27631755; PMCID: PMC5055785.
3. Boehnke KF, Litinas E, Clauw DJ. Medical Cannabis Use Is Associated With Decreased Opiate Medication Use in a
Retrospective Cross-Sectional Survey of Patients With Chronic Pain. J Pain. 2016;17(6):739-44. doi:
10.1016/j.jpain.2016.03.002. PubMed PMID: 27001005.
4. Haroutounian S, Ratz Y, Ginosar Y, Furmanov K, Saifi F, Meidan R, Davidson E. The Effect of Medicinal Cannabis
on Pain and Quality-of-Life Outcomes in Chronic Pain: A Prospective Open-label Study. Clin J Pain.
2016;32(12):1036-43. doi: 10.1097/AJP.0000000000000364. PubMed PMID: 26889611.
5. Gruber SA, Sagar KA, Dahlgren MK, Racine MT, Smith RT, Lukas SE. Splendor in the Grass? A Pilot Study
Assessing the Impact of Medical Marijuana on Executive Function. Front Pharmacol. 2016;7:355.
doi:10.3389/fphar.2016.00355. PubMed PMID: 27790138; PMCID: PMC5062916.
6. Bradford AC, Bradford WD. Medical Marijuana Laws Reduce Prescription Medication Use In Medicare Part D. Health
Aff (Millwood). 2016;35(7):1230-6. doi: 10.1377/hlthaff.2015.1661. PubMed PMID: 27385238.
7. Bradford AC, Bradford WD. Medical Marijuana Laws May Be Associated With A Decline In The Number Of
Prescriptions For Medicaid Enrollees. Health Aff (Millwood). 2017;36(5):945-51. doi: 10.1377/hlthaff.2016.1135.
PubMed PMID: 28424215.
8. Roberts JD, Gennings C, Shih M. Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and
morphine. European journal of pharmacology. 2006;530(1-2):54-8. Epub 2005/12/27. doi:
10.1016/j.ejphar.2005.11.036. PubMed PMID: 16375890.
9. Abrams DI, Couey P, Shade SB, Kelly ME, Benowitz NL. Cannabinoid-opioid interaction in chronic pain. Clinical
pharmacology and therapeutics. 2011;90(6):844-51. Epub 2011/11/04. doi: 10.1038/clpt.2011.188. PubMed PMID:
22048225.
10. Wilson AR, Maher L, Morgan MM. Repeated cannabinoid injections into the rat periaqueductal gray enhance
subsequent morphine antinociception. Neuropharmacology. 2008;55(7):1219-25. doi:
10.1016/j.neuropharm.2008.07.038. PubMed PMID: 18723035; PMCID: 2743428.
11. Smith PA, Selley DE, Sim-Selley LJ, Welch SP. Low dose combination of morphine and delta9- tetrahydrocannabinol
circumvents antinociceptive tolerance and apparent desensitization of receptors. European journal of pharmacology.
2007;571(2-3):129-37. Epub 2007/07/03. doi: 10.1016/j.ejphar.2007.06.001. PubMed PMID: 17603035; PMCID:
2040345.
12. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain – United States, 2016.
MMWR Recomm Rep. 2016;65(1):1-49. doi: 10.15585/mmwr.rr6501e1. PubMed PMID: 26987082.
13. NASEM. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for
Research. Washington (DC) 2017.
14. Reiman A, Welty M, Solomon P. Cannabis as a Substitute for Opioid-Based Pain Medication: Patient Self Report.
Cannabis Cannabinoid Res. 2017;2(1):160-6. doi: 10.1089/can.2017.0012. PubMed PMID: 28861516; PMCID:
PMC5569620.
15. Hurd YL, Yoon M, Manini AF, Hernandez S, Olmedo R, Ostman M, Jutras-Aswad D. Early Phase in the Development
of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage. Neurotherapeutics.
2015;12(4):807-15. doi: 10.1007/s13311-015-0373-7. PubMed PMID: 26269227; PMCID: PMC4604178.
16. Raby WN, Carpenter KM, Rothenberg J, Brooks AC, Jiang H, Sullivan M, Bisaga A, Comer S, Nunes EV. Intermittent
marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence. Am J Addict.
2009;18(4):301-8. doi: 10.1080/10550490902927785. PubMed PMID: 19444734; PMCID: PMC2753886.


Leave a comment

German Medical Marijuana patients continued suffering despite the new law – from Hemp Magazine

After a small request from the federal government that the health insurance funds have to approve a therapy with medical cannabis before the statutory health insurance takes over the costs for the treatment, Frank Tempel, a sign of the drug policy of the left fraction, gives answers Questions that could be asked by those concerned. Meanwhile, the draft of a cannabis control law of the Green Bundestag fraction of March 2015 was rejected.
As beautiful as the new “Act on the Amendment to Narcotic Drugs and Other Provisions”, which came into effect on March 10, 2017, it raises a few dark shadows that could have a negative impact on the patient in the future. One of the central problems is the cost of a cannabis therapy by statutory health insurance. While pain patients receive the treatment in most cases, the world looks quite different in mental disorders, for example cases of ADHD or depression, Tempel reports on his website.
Requests for reimbursement would often be rejected in these patients. This also applies to patients who had already received a special permit from cannabis therapy from the “Federal Institute for Drugs and Medical Devices” prior to the entry into force of the Act. Because of this, it was already the first complaints of patients against the health insurance companies, it goes on. Temple also drew attention to the fact that there are some tips and hints to be able to claim the right to the costs.
The right to therapy with cannabis may be to patients if “a generally accepted medical standard” is either “not available” or “can not be used”, as well as “a not distant prospect perceptible positive effect on the course of the disease or on serious symptoms, “the Federal Government said in response to the small request from the left. According to the government, the treating physician must confirm these criteria and justify his decision against the health insurance company. But what helps if the cash registers?
Support the doctor
Tempel points out that it is easy for health insurance funds, especially through the second criterion, to refuse an application for the costs. This would be due to the lack of studies on the use of cannabis as a medicine, explains the deputy chairman of the Committee on Internal Medicine of the Bundestag. The 48-year-old, therefore, recommends “to refer to the introduction of a companion for which the patients have to participate if the costs of the therapy are to be reimbursed.”
In addition, he advises the physicians to assist in the completion of the application, since the health insurance companies would reject it at the smallest form defect. A sample application that could make life easier for the doctors offers the “Arbeitsgemeinschaft Cannabis as medicine” on their website http://www.cannabis-med.org . In order to take the perhaps still inexperienced doctor in this area further, the politician recommends in a discussion with the doctor also, professional-medically-based information to these to pass.
Where can I find a suitable doctor?
But already the search for a supervising doctor prepares the patient difficulties. The doctors would have little desire for more of the unpaid work and the effort they have to do, so temples. This is understandable. In addition to disputes with the health insurance companies, the treating physician must collect information about his patient and then pass it on to the “Federal Institute for Drugs and Medical Devices”. Temple once again refers to the “Cannabis as a medical community”, which can be asked for a doctor from the region who already has experience in prescribing medicinal hemp.
What to do if the cash office refuses?
If the applications, which are usually processed by the health insurance company within three weeks, but which can be withdrawn at the time the medical service is examined for examination of the application for five weeks, Tempel recommends that the supervisory authority, the relevant cash register. A protest may also be filed against the decision. A generator can also be found on the website of the “Arbeitsgemeinschaft Cannabis als Medizin”.
By a contradiction, the patient can also provide additional time, so that further advice can be brought into the boat, informs Tempel and writes to the following: “Do you have only courage to protest against the refusal of the health insurance company. There are cases in which the health insurance funds have approved it after the objection and a new application for reimbursement. “As a last option, the politician is considering taking legal action before the Social Court. The “Cannabis Consortium for Medicine” is even considering the support of the patient in court cases, provided that good prospects for success would exist, Tempel continues.
The Greens fail with a bill
Even though Germany has taken a clear step in the handling of marijuana through the “Act for the Amendment of Narcotic Drugs and Other Provisions” in the recent past, there are, of course, still sets-up parameters that can be worked on. The Greens tried their luck already two years ago in March 2015.
At that time, the Bundestag’s party draft a cannabis control law and presented it to the health committee of the Bundestag, which was voted on Wednesday. Although the Greens had the left fraction on their side, they failed with their draft, however, to the factions of the Union and the SPD, who opposed it.
The Greens drew attention to the fact that the cannabis control law had been an alternative to the prohibiting policy which had taken place here because it was “completely failed.” In the case of marijuana, which is the most widely used illegal drug in Germany, the criminal law provisions of the Narcotics Act should no longer apply , so the desire of the Greens. Instead, they pleaded in their template for a controlled, legal market with a regulated cannabis trading chain.
“The no from the Union and the SPD to our cannabis control law is a no to youth and consumer protection,” the “Ärtzeblatt” cites Greens Group spokeswoman Katja Dörner and the spokesman for drug and addiction policy, Harald Terpe. Cannabis is not harmless, the party made clear, precisely because of this, youth and consumer protection should not be left to the dealer.


Leave a comment

Kiffen on recipe? The cannabis doctor of Berlin

– by Thorsten Harmsen

Eva Milz (44) treats patients with medical cannabis. It means that the possibilities of the medium have not been fully developed.

Legal killing on prescription – critics see the meaning of the law, which the Bundestag decided in March. For the first time, doctors can prescribe cannabis. One of them is Eva Milz, psychiatrist with practice in Johannisthal.

The flowers of the hemp plant can relieve severe symptoms of the disease: – chronic pain, spastic paralysis, nausea, anxiety. But the plant can do more. This is my medical profession, who has dedicated himself to the development of the therapeutic potential of cannabis. There are only a few in Germany who believe that it is worth using cannabis as a therapy attempt .

Eva Milz knows about the restraint of many colleagues when dealing with the medicine. Because physicians are only allowed to prescribe medicinal cannabis if standard therapies do not help or have a “not very distant prospect of noticeable positive development on the course of the disease”. “Most doctors talk out and think you have to wear your head under your arm before you get cannabis,” says Eva Milz. But the fear of the means is unfounded.

Cannabis has already been used as a medicine in antiquity, including China and Egypt. This experience has been lost, says Eva Milz. For example, no medicine student learns that the body has many docking points for the substances from the hemp plant. These would be used to control messengers which ensure the functioning of nerve cells. “That’s part of every textbook,” says Eva Milz.

Nationwide it was about a thousand patients

She worked in many clinics, most recently as a psychiatrist at the Unfallkrankenhaus Berlin. She knows the spectrum of the means of modern medicine. It was addressed to cannabis as a therapy option for the first time in 2002. She then worked in patient advice for the medicine portal of a specialist publishing house. Multiple sclerosis patients, to whom she was talking, had discovered by accident – for example, when smoking a joint – that cannabis helps them as no other remedy.

Many asked if it was not legal. In working for the Federal Center for Health Education, Eva Milz again met people who were suffering from attention deficit hyperactivity disorder (ADHD) and reported that they were permanently in a state of decline after cannabis withdrawal.

When she founded her practice in 2015, she co-operated with the doctor, Franjo Grotenhermen, chairman of the Cannabis Consortium for Medicine (ACM). Eva Milz reviewed medical reports from patients from all over Germany and sent them to the Federal Institute for Drugs and Medical Devices. At the time, this granted exemptions for patients who were allowed to use cannabis.

Nationwide, it was about a thousand – 20 percent of ADHD patients. Those affected can not concentrate, neither learn nor work. They often find themselves in an offside position because they have an outcrop. But after the consumption of cannabis, they were able to concentrate, were able to learn and work. Many got their impulses under control.

Cannabis plant
The flowers of the hemp plant can alleviate serious symptoms.
Photo: Imago / CTK Photo
In ADHD, the THC appears to promote the concentration and focus of patients

According to Eva Milz, this is due to the variety of the ingredients of the hemp plant, especially the cannabinoids. “The main player that most know is the THC,” she says, expelled tetrahydrocannabinol. It has a harsh, psychoactive effect. “Cannabidiol, CBD, is quite unknown,” says Eva Milz. It acts like an opponent to the THC: anxiety and cramping, relaxing and anti-inflammatory. In addition, there are other cannabinoids, essential oils and aromas.

The components worked together. In ADHD, for example, the THC appears to be mainly focussing on the concentration and focus of the patient, says Eva Milz. The CBD probably solve the fear. Because impulsiveness and austerity have much to do with fear.

Perplexed, the psychiatrist read in the doctor’s letters that it was always the parents of young ADHD patients who asked if one could not legalize cannabis. Those who were closest to those affected had noticed that conventional drugs such as Ritalin slowed the sufferers, but also slowed creativity and liveliness. Cannabis had been an alternative.

In multiple-sclerosis patients, the agent for pain and muscle cramps is also effective, because both parts – THC and CBD – are also present, says Eva Milz. A list of 14 varieties of medicinal cannabis blossoms with different dosages shows how diverse the remedy is.

“I have been waiting for the critical questions of cannabis opponents for two years”

Many people think of cannabis first drug, possible addiction and its consequences. But even these are well controlled by an experienced doctor, says Eva Milz. It is reminiscent of conventional drugs that trigger the most severe dependencies. Cannabis with its comparatively mild withdrawal symptoms could possibly serve as a substitute.

One missing Eva Milz: “I have been waiting for the critical questions of cannabis opponents for two years, but I do not get them.” Instead, desperate patients came to her, who had been thrown out by other doctors – as supposedly addicts who were on detours Material wanted to come.

The doctor is inter alia with researchers at a university in conversation. Studies are being conducted on the use of cannabis flowers in Tourette’s syndrome, ADHD and other diseases where the drug is already being used. “I would like to have 30 to 50 preparations, which I can use as necessary,” she says. It is used for inflammatory diseases, anxiety, sleep disorders, neurodermatitis, migraine and other ailments.

One problem is the cost. The health insurance funds approve only about half of the applications. But a treatment can cost up to 3000 euros a month. For one gram of cannabis, the pharmacies demand 22 euros. Many could not afford it.

– Quelle: http://www.berliner-kurier.de/28240224 ©2017


Leave a comment

CHONG’S CHOICE CBD – by Diamond CBD, Inc.

PotNetwork Holding Inc. (OTC: POTN) announced that Tommy Chong, counter-culture legend, marijuana legalization advocate and half of the incomparable creative team of Cheech & Chong, has selected its subsidiary, Diamond CBD, Inc., as his partner to introduce a proprietary brand of hemp-derived CBD oil products, under the brand name, Chong’s Choice CBD. Tommy’s brand will include CBD-infused edibles, concentrated solvent-free vaping additives and hemp oil tincture drops. Production of the new line is expected to begin within a month, with immediate online availability. As Tommy’s partner, Diamond CBD will offer the new brand to its distribution channels and assist in overall marketing. Tommy Chong stated, “I use Diamond CBD products and love them. They help me relax and often soothe the occasional pain of an old stoner.” He continued, “I want to be part of this 21st century CBD revolution which promises unprecedented health benefits to millions of people and Diamond CBD has a premier line of products, many of which I am pleased to bring to the market under my brand.”

Gary Blum, Chief Executive Officer, PotNetwork Holding, added, “We are honored to get to work closely with Tommy, and anticipate this partnership will further solidify Diamond CBD as the category leader in beneficial CBD products.”

 

eb5391d6285786e92b2504fb296dea97